Coherus Oncology (CHRS) Return on Invested Capital (2021 - 2023)
Coherus Oncology (CHRS) posted Return on Invested Capital of 0.36% for Q4 2023, down 244.74% sequentially from 0.1% in Q3 2021.
Coherus Oncology (CHRS) Return on Invested Capital (2021 - 2023) Analysis & Trends
Coherus Oncology has reported Return on Invested Capital for 2 years, with the latest figure at 0.36% in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.04% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -0.17% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.35% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -0.36% |
| Sep 30, 2021 | -0.10% |